Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu C...

2023-05-18 16:00 1915

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswi...

2023-05-18 14:00 3319

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. * The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolo...

2023-05-18 11:53 2876

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncologyand Antengene's third drug candidate to enter clinical studies in the U.S. - The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacolog...

2023-05-18 02:47 2545

Providence-based "Biotech start up" EpiVax Celebrates 25th Anniversary

PROVIDENCE, R.I., May 17, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is celebrating its 25th birthday by renewing the company's commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition, EpiVax is celebrating the work ...

2023-05-17 23:49 2309

Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023

SHANGHAI, May 17, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, is showcasing multiple data presentations at the American Society of Gene and Cell Therapy ...

2023-05-17 18:00 1858

Insilico Medicine Successfully Explores the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry

NEW YORK, May 17, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it groundbreakingly combines two rapidly developing technologies, quantum computing and generative AI to explore the lead candidat...

2023-05-17 18:00 2853

Inclusion of Recbio In the MSCI China Small Cap Index

TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes onMay 12, 2023, and the Company has ...

2023-05-17 14:01 5492

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2023-05-17 08:30 2616

Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

SUZHOU, China, May 17, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces encouraging phase I cl...

2023-05-17 08:17 2161

Innovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, May 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-05-17 08:00 4122

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

SHANGHAI, May 17, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-...

2023-05-17 07:48 3645

DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS

* Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. * Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA dama...

2023-05-17 07:00 2054

Fresh2 Reports Fiscal Year 2022 Annual Financial Results

NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and entering into the operation of a ...

2023-05-17 04:15 2419

Boan Biotech's BA1202 Approved for Clinical Trial

-The First Novel CEA/CD3 Bispecific Antibody in China- YANTAI, China, May 16, 2023 /PRNewswire/ -- Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation ofChina's National Medical Products A...

2023-05-16 22:02 5279

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

- Reorganizing the global sales networks and enhancing its capabilities to get global approvals for new drug - Accelerating value of the new drug pipelines SEOUL, South Korea, May 16, 2023 /PRNewswire/ -- DxVx announced on the 16th, the board of directors appointedYong Gu Lee as the new CEO and ...

2023-05-16 21:00 2477

DxVx appoints Yong Gu Lee as new CEO and Kevin Kwon as the new president

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan

GAITHERSBURG, Md., May 16, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious d...

2023-05-16 19:00 1966

Cambrex Completes Expansion of Snapdragon Chemistry Facility in Waltham, Massachusetts

EAST RUTHERFORD, N.J., May 16, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that Snapdragon Chemistry has completed the se...

2023-05-16 18:00 2200

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. * InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April ...

2023-05-16 16:00 1807

LG Chem Targets Sixfold Sales Growth in Battery Materials to KRW 30 Trillion by 2030

- Will expand sales portion in battery materials, sustainability business and innovative new drugs - Aims to accelerate in reaching net zero by 2050 by proactively building an integrated low-carbon management system SEOUL, South Korea, May 15, 2023 /PRNewswire/ -- LG Chem today announced i...

2023-05-16 09:34 2462

1 ... 64 65 666768 69 70 ... 294